Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells
about
Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a reviewTxnip ablation reduces vascular smooth muscle cell inflammation and ameliorates atherosclerosis in apolipoprotein E knockout miceProbing the substrate specificity of the intracellular brain platelet-activating factor acetylhydrolaseAtherogenesis in perspective: hypercholesterolemia and inflammation as partners in crimeMitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathwayLipid peroxidation generates biologically active phospholipids including oxidatively N-modified phospholipidsSREC-II, a new member of the scavenger receptor type F family, trans-interacts with SREC-I through its extracellular domainCeruloplasmin enhances smooth muscle cell- and endothelial cell-mediated low density lipoprotein oxidation by a superoxide-dependent mechanism.The role of oxidized phospholipids in atherosclerosis.Import and fate of fluorescent analogs of oxidized phospholipids in vascular smooth muscle cells.Polyunsaturated phospholipids promote the oxidation and fragmentation of gamma-hydroxyalkenals: formation and reactions of oxidatively truncated ether phospholipidsThe biology of reactive intermediates in systemic lupus erythematosus.Ultraviolet B radiation of human skin generates platelet-activating factor receptor agonists.Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemiaIdentification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist.Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosusCirculating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolaseAntibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's diseaseAssociation of postprandial hyperglycemia with in vitro LDL oxidation in non-smoking patients with type 1 diabetes--a cross-sectional studyPlatelet-activating factor, a pleiotrophic mediator of physiological and pathological processes.Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation.Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New GuineaModulation of growth factor gene expression in vascular cells by oxidative stress.Antigen-tailored therapy based on the inflammatory theory of atherosclerosis.Correlation between small dense low-density lipoprotein cholesterol and carotid artery intima-media thickness in a healthy Chinese populationAldose reductase-catalyzed reduction of aldehyde phospholipidsChanges in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.Structural identification and cardiovascular activities of oxidized phospholipids.Toxicity of oxidized phospholipids in cultured macrophagesThe biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus.Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study.Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein.UVB radiation-mediated inhibition of contact hypersensitivity reactions is dependent on the platelet-activating factor system.Understanding the connection between platelet-activating factor, a UV-induced lipid mediator of inflammation, immune suppression and skin cancer.Oxidized phospholipids: biomarker for cardiovascular diseases.Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells.Escherichia coli Braun Lipoprotein (BLP) exhibits endotoxemia - like pathology in Swiss albino mice.Alcohol drinking and cardiac risk.Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.
P2860
Q26991853-55640905-BD00-4AF8-875C-6A3E357D24E7Q27332439-E9716F9A-E09D-4952-AE45-166011C0239CQ27619562-B2F3D157-C5A0-4972-B7DB-025B5869D3B3Q28212769-E606ACD8-5795-490E-8768-019FE0366887Q28361224-50777B34-3847-493B-8E00-7A3648B9181FQ28389004-8C685574-F24E-4C0F-93DB-2969FCF5A6C6Q28507065-2145F32C-1D1B-4B86-A1D1-73E30756DEEEQ30423997-96EDBAEB-25B7-4EEC-8B9F-D09872238464Q30436606-98F79DB8-37C1-4A5B-8627-959D21E00D20Q33265039-F0878C11-6564-4DF8-B523-ED04B01C80C8Q33719295-7D145797-9C41-4DBD-9E1F-62BED6C22B65Q33802441-5051849C-F4DE-415E-AB03-CA170B909B49Q34020597-6F286437-CC58-4DE3-96C5-089A803DFC80Q34188093-9E5455CF-B735-4FC9-A1FB-690A9D0838E5Q34466845-1D70FBBE-E729-458E-947B-D5E6895D024BQ34613997-1B790587-F090-455C-B5C6-91D8EB9B6700Q34670677-25D4DBBE-5B90-4565-A7C3-95EE5BC96C0BQ35072824-5ECDA59E-F489-427F-BC8A-ADD7916E87FEQ35612693-338F3E8E-09F2-47A0-92C5-EE16CE830C19Q35621992-59498454-980C-4C13-9AFA-1731B4EB1674Q35655728-54E5D6C9-0394-4DFD-8288-A3364EBB6AC6Q35752098-F21F8B12-1879-4EA7-868E-5965A928CFF4Q35888600-0078D358-4B82-4413-993B-EC09B3505FE0Q35918521-4F7DA643-7A45-4C56-80DE-095DC73BFEF9Q36223515-68177173-3204-4C6F-A72D-B891E8920CB2Q36330024-617E8CAB-3F8A-4F51-A146-6884CBC7A056Q36436569-E902CD5C-394D-4665-8E78-E813B9B8BE9AQ36456339-D086F4D6-4E41-49C0-92D0-6C110FEB7918Q36498570-4ACA99E5-CBA7-460D-8BDC-8503DC99AB87Q36544017-15D99CAA-34AE-4716-8F5F-D0133082AB0BQ36757006-429E9D20-E7D6-4942-BCE4-CDBBBDF42A3AQ36838426-7AFCC8D4-2B16-499A-95E8-3C4F7F4077ACQ37098670-1AB20C55-0354-40E0-A6A5-F32F5B3324E5Q37156655-00C01B9E-8C07-4A34-80F5-AA67FE18A88FQ37200929-E23FEEC1-EEE9-4398-95D1-6CE2B20FCAB6Q37207411-F6F3DE8E-50B5-483B-B9E9-BED50B381B96Q37307082-172C50A2-6B5B-4059-88BC-3E8F1B4212D7Q37352246-E307B5DF-2894-4245-9C09-36DF87225C0AQ37358413-ABC05113-38CE-480D-AE61-E8BCB043D189Q37358421-17A09BF9-1595-42DE-9EB7-AF7EDE8D6CF9
P2860
Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Oxidatively modified LDL conta ...... growth of smooth muscle cells
@ast
Oxidatively modified LDL conta ...... growth of smooth muscle cells
@en
type
label
Oxidatively modified LDL conta ...... growth of smooth muscle cells
@ast
Oxidatively modified LDL conta ...... growth of smooth muscle cells
@en
prefLabel
Oxidatively modified LDL conta ...... growth of smooth muscle cells
@ast
Oxidatively modified LDL conta ...... growth of smooth muscle cells
@en
P2093
P2860
P356
P1476
Oxidatively modified LDL conta ...... growth of smooth muscle cells
@en
P2093
D M Stafforini
G A Zimmerman
S M Prescott
T M McIntyre
P2860
P304
P356
10.1172/JCI118288
P407
P577
1995-11-01T00:00:00Z